Customizable facility

By designing customizable facilities, including shells, central units and module units, the problem of difficult configuration and expansion of traditional facilities is solved, and the product line is quickly built and expanded, and production efficiency and resource utilization efficiency are improved.

CN118911486APending Publication Date: 2024-11-08隆扎有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410912458.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-03-10
Filing Date
2017-03-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The structure of traditional manufacturing facilities limits the configuration and expansion of product lines, makes it difficult to effectively utilize public resources, and is difficult to quickly modify to adapt to new manufacturing processes, resulting in increased facility downtime.

Method used

Designed a customizable facility that includes housing, central unit and module units, which maximizes the speed and convenience of manufacturing capabilities through flexible configuration and arrangement, allowing users to manufacture multiple products, including fermentation, in a cleaning room environment. Units, pre-virus units, post-virus units, etc., module units communicate with central units to provide utility.

Benefits of technology

It has achieved rapid construction and expansion of product lines, reduced capital expenditure and construction timelines, improved global design standardization, reduced fixed asset demand, reduced on-site congestion, and improved production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118911486A_ABST
    Figure CN118911486A_ABST
Patent Text Reader

Abstract

The invention discloses a method for constructing a customizable facility. The method comprises the following steps: providing a shell; supporting the bioreactor on the ground within the housing; installing a first stage feature in a first stage on the ground; installing a second stage feature in the second stage; and installing additional features in at least one subsequent stage, wherein the customizable facility is configured to manufacture at least one pharmaceutical product. Also disclosed is a customizable facility for manufacturing at least one pharmaceutical product comprising five rows of zones, the customizable facility comprising: a first row comprising a plurality of purification zones; a second row comprising a plurality of fermentation zones; a third row comprising at least one central utility zone; a fourth row comprising a plurality of fermentation zones; a fifth row comprising a plurality of purification zones; and adding an extension of an additional region to each row.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a patent application with an application date of March 10, 2017, application number 201780026484.9, and invention name “Customizable Facility”. The entire contents of the above application are incorporated herein by reference.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 306,556, filed on March 10, 2016, which is incorporated herein by reference in its entirety for all purposes. Field of the Invention

[0004] The present disclosure relates to a customizable facility that enables a user to manufacture multiple products within the facility. In particular, the present disclosure relates to a customizable facility for manufacturing products in a clean room environment. Background Art

[0005] The traditional structure for manufacturing products such as monoclonal antibodies and microbial products does not allow for efficient use of the space of the structure. The layout of the traditional structure usually limits them to be easily configured or expanded to manufacture new product lines. Therefore, a manufacturing facility is needed that allows users to effectively use common resources between product lines and easily modify the facility to adapt to new manufacturing processes or new production lines with reduced facility downtime. Summary of the invention

[0006] The present disclosure provides a customizable facility for manufacturing at least one product, which utilizes at least one production process (e.g., a production process using a fermentation unit and a purification unit). According to one aspect of the present disclosure, the customizable facility comprises a housing, at least one central unit positioned within the housing, and at least one modular unit, each modular unit being positioned within the housing. The housing, central unit, and modular units are configured and arranged to maximize the speed and convenience of modifying different ranges of manufacturing capabilities.

[0007] According to another aspect of the present disclosure, a customizable facility for manufacturing at least one pharmaceutical product comprises at least one central unit.At least one modular unit communicates with the at least one central unit such that the at least one central unit provides utilities to the at least one modular unit.

[0008] In some embodiments, the customizable facility includes a housing, wherein at least one central unit is at least partially positioned within the housing, and at least one modular unit is at least partially positioned within the housing.

[0009] In some embodiments, at least one modular unit comprises at least one of: a fermentation unit, a pre-viral unit, a post-viral unit, a utility space, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a fill-finish unit, a dosage preparation unit, and a packaging unit.

[0010] In some embodiments, at least one of the at least one modular unit is directly adjacent to at least one central unit.

[0011] In some embodiments, at least one modular unit comprises a plurality of modular units arranged to maximize the number of modular units within the housing while minimizing the footprint of the housing.

[0012] In some embodiments, each modular unit of the plurality of modular units is directly adjacent to at least one of the at least one central unit and another one of the plurality of modular units.

[0013] In some embodiments, at least one central unit and a plurality of modular units form a hub and spoke formation.

[0014] In some embodiments, at least one central unit and a plurality of modular units are arranged in an H-shaped configuration.

[0015] In some embodiments, the customizable facility comprises a bioreactor supported on the ground within a housing.

[0016] In some embodiments, the customizable facility comprises a bioreactor supported within at least one of the modular units.

[0017] In some embodiments, the outer wall of the customizable facility is one of: formed by the shell, which completely seals the at least one central unit and the at least one modular unit; and formed by at least one of the outer walls of the shell and the at least one central unit and the outer walls of the at least one modular unit.

[0018] In some embodiments, the shell includes at least one side wall, which surrounds the at least one central unit and the at least one modular unit, and a top cover fixed to the upper edge of the at least one side wall, and the top cover extends over the at least one central unit and the at least one modular unit.

[0019] In some embodiments, at least one of the at least one modular unit is a clean room.

[0020] In some embodiments, at least one modular unit is configured for cell therapy operations.

[0021] According to another aspect of the present disclosure, a method for assembling a facility for manufacturing at least one pharmaceutical product comprises: providing at least one central unit; and providing at least one modular unit, wherein the at least one modular unit communicates with the at least one central unit such that the at least one central unit provides utility to the at least one modular unit.

[0022] In some embodiments, the method includes providing a housing; positioning the at least one central unit at least partially within the housing; and positioning the at least one modular unit at least partially within the housing.

[0023] In some embodiments, at least one modular unit comprises at least one of: a fermentation unit, a pre-viral unit, a post-viral unit, a utility space, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a filling-finished product unit, a dosage preparation unit, and a packaging unit.

[0024] In some embodiments, the at least one modular unit comprises a plurality of modular units arranged to maximize the number of modular units within the housing while minimizing the footprint of the housing.

[0025] In some embodiments, each modular unit of the plurality of modular units is directly adjacent to at least one of the at least one central unit and another of the at least one modular unit.

[0026] In some embodiments, at least one central unit and a plurality of modular units form a hub-and-spoke structure.

[0027] In some embodiments, at least one central unit and a plurality of modular units are arranged in an H-shaped configuration.

[0028] In some embodiments, the method comprises one of: supporting a bioreactor on a floor within the housing and supporting the bioreactor within one of the at least one modular unit.

[0029] In some embodiments, the outer wall of the customizable facility is one of: formed by the shell, which completely seals the at least one central unit and the at least one modular unit; and formed by at least one of the outer walls of the shell and the at least one central unit and the outer walls of the at least one modular unit.

[0030] In some embodiments, the shell includes at least one side wall, which surrounds the at least one central unit and the at least one modular unit, and a top cover fixed to the upper edge of the at least one side wall, and the top cover extends over the at least one central unit and the at least one modular unit.

[0031] In some embodiments, at least one drug product is a biosimilar product.

[0032] In addition to the above, this application also involves the following projects:

[0033] 1. A method for constructing a customizable facility, the method comprising:

[0034] providing a housing comprising at least one side wall and a roof, wherein the housing is supported on a footing fixed to the ground;

[0035] supporting a bioreactor on a floor within the housing;

[0036] installing first-stage features in the first stage on the ground, the first-stage features comprising an air-controlled entryway, a gowning area, a utility area, a first manufacturing wing, a first office space, a first set of modular units, and at least one corridor connecting at least two first-stage features to each other, the first set of modular units having a first modular unit being a fermentation unit, a second modular unit being a pre-viral unit, a third modular unit being a post-viral unit, a fourth modular unit being a fill-finished product unit, a fifth modular unit being a dosage compounding unit, and a sixth modular unit being a packaging unit;

[0037] installing in a second phase second phase features, the second phase features comprising a second manufacturing wing, a second office space, and a second group of modular units, the second group of modular units having a seventh modular unit being a fermentation unit, an eighth modular unit being a pre-viral unit, a ninth modular unit being a post-viral unit, a tenth modular unit being a fill-finished product unit, an eleventh modular unit being a dosage formulation unit, and a twelfth modular unit being a packaging unit, the second group of modular units being vertically located on at least one level above the bioreactor and the first group of modular units; and

[0038] installing additional features in at least one subsequent stage, the additional features comprising additional groups of module units and additional manufacturing wings,

[0039] wherein the additional feature is positioned horizontally or vertically adjacent to the first manufacturing wing or the second manufacturing wing, and

[0040] Wherein the customizable facility is configured to manufacture at least one pharmaceutical product.

[0041] 2. The method of claim 1, wherein the infill-finished unit of the second set of modular units has a single floor with a floor area of ​​1,500 square meters.

[0042] 3. The method of item 2, wherein the fill-finished product unit further comprises a middle layer for an HVAC plant room.

[0043] 4. The method of item 2, wherein the filling-finished product unit further comprises a free space arranged directly adjacent to the filling-finished product unit, the free space together with the filling-finished product unit having a floor area of ​​3,000 square meters.

[0044] 5. The method of item 1, wherein the first group or the second group of module units comprises a 2k module having a single layer with a footprint of 1,500 square meters, and the 2k module can seal a 2,000-liter container.

[0045] 6. The method of item 5, wherein the 2k module further comprises a middle layer for an HVAC plant room.

[0046] 7. The method of item 5, wherein the 2k module further comprises a free field disposed directly adjacent to the 2k module, the free field together with the 2k module having a floor area of ​​3,000 square meters.

[0047] 8. The method of item 1, wherein the first group or the second group of modules comprises a 5k module having a single layer with a footprint of 3,000 square meters, and the 5k module can seal a 5,000-liter container.

[0048] 9. The method of item 8, wherein the 5k module further comprises a middle layer for an HVAC plant room.

[0049] 10. The method of item 1, wherein the first group or the second group of modules comprises a 15k module, wherein the 15k module has a first layer and a second layer.

[0050] 11. The method of claim 10, wherein the 15k module has a footprint of 3,000 square meters and can seal a 15,000 liter container.

[0051] 12. The method of item 10, wherein the 15k module further comprises a local HVAC unit, a clean-in-place (CIP) unit, and a temperature control unit (TCU).

[0052] 13. The method of claim 10, wherein the second layer of the 15k module extends vertically above the first layer of the 15k module.

[0053] 14. The method of claim 10, wherein the first layer of the 15k modules and the second layer of the 15k modules together have an area of ​​6,000 square meters.

[0054] 15. The method of item 1, wherein the customizable facility comprises a 20k module having a first layer, a second layer, and a third layer.

[0055] 16. The method of claim 15, wherein the 20k module has a footprint of 3,000 square meters and can seal a 20,000 liter container.

[0056] 17. The method of item 15, wherein the second layer of the 20k module extends vertically above the first layer of the 20k module, and the third layer of the 20k module extends vertically above the first layer of the 20k module and the second layer of the 20k module.

[0057] 18. The method of claim 15, wherein the first layer of the 20k module, the second layer of the 20k module, and the third layer of the 20k module together have an area of ​​9,000 square meters.

[0058] 19. The method of item 1, wherein the customizable facility further comprises a yard directly adjacent to the customizable facility, the yard comprising a processing area for processing equipment and materials.

[0059] 20. The method of item 1, wherein the customizable facility further comprises a warehouse area sealed within the housing.

[0060] 21. A customizable facility for manufacturing at least one pharmaceutical product, comprising five rows of zones, said customizable facility comprising:

[0061] a first row, which comprises a plurality of purification zones;

[0062] the second row, which contains multiple fermentation zones;

[0063] a third row, which includes at least one central utility zone;

[0064] the fourth row, which contains multiple fermentation zones;

[0065] a fifth row comprising a plurality of purification zones; and

[0066] An expansion that adds two additional purification zones to the first row, two additional fermentation zones to the second row, two additional fermentation zones to the fourth row, and / or two additional purification zones to the fifth row.

[0067] 22. The customizable facility of item 21, wherein the facility does not include a housing.

[0068] 23. The customizable facility of item 21 wherein said central utility zone provides utility to each of said other zones.

[0069] 24. The customizable facility of item 21, wherein the first row comprises three purification zones, the second row comprises three fermentation zones, the fourth row comprises three fermentation zones, and / or the fifth row comprises three purification zones.

[0070] 25. The customizable features of item 21, further comprising a utility extension that adds additional utility area to said third row.

[0071] 26. The customizable facility of item 21, further comprising a housing that seals all of the first row to the fifth row.

[0072] 27. The customizable facility of item 21, wherein the second row is adjacent to the first row, the third row is adjacent to the second row, the fourth row is adjacent to the third row, and the fifth row is adjacent to the fourth row.

[0073] 28. The customizable facility of item 25, wherein the expansion adds two additional purification zones to the first row, two additional fermentation zones to the second row, two additional fermentation zones to the fourth row, and two additional purification zones to the fifth row.

[0074] 29. The customizable facility of item 28, wherein the expansion further adds an equal number of additional purification zones to the first row and the fifth row, and an equal number of additional fermentation zones to the second row and the fourth row.

[0075] 30. The customizable facility of item 21, wherein the expansion further comprises at least one additional purification zone to the first row, at least one additional fermentation zone to the second row, at least one additional fermentation zone to the fourth row, and / or at least one additional purification zone to the fifth row. BRIEF DESCRIPTION OF THE DRAWINGS

[0076] The drawings are not intended to be drawn to scale. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:

[0077] Figure 1 is a top view of an embodiment of a customizable facility according to the present disclosure;

[0078] Figure 2A yes Figure 1 A perspective view of an embodiment of the invention;

[0079] Figure 2B yes Figure 1 A perspective view of an embodiment of the invention showing the locations of components within the customizable facility;

[0080] Figure 2C yes Figure 1 a perspective view of an embodiment of the invention showing the location of another component within the customizable facility;

[0081] Figure 2D yes Figure 1 a perspective view of an embodiment of the invention showing the location of another component within the customizable facility;

[0082] Figure 2E yes Figure 1 a perspective view of an embodiment of the invention showing the location of another component within the customizable facility;

[0083] Figure 3A is an exploded view of an embodiment of a modular unit according to the invention.

[0084] Figure 3B is an exploded view of another embodiment of a modular unit according to the present invention.

[0085] Figure 3C is an exploded view of another embodiment of a modular unit according to the present invention.

[0086] Figure 3D is an exploded view of another embodiment of a modular unit according to the present disclosure.

[0087] Figure 3E is an exploded view of another embodiment of a modular unit according to the present invention.

[0088] Figure 4 is a front perspective cutaway view of an embodiment of a customizable facility according to the present disclosure.

[0089] Figure 5 is a perspective view of a group of modular units and a central unit arranged in an H-shaped layout;

[0090] Figure 6 is a top view of a group of module units and a central unit arranged in an H-shaped layout;

[0091] Figure 7 is its perspective view;

[0092] Figure 8 is a top view of the modular units and the central unit arranged in another arrangement within the housing;

[0093] Fig. 9 is a top view of another arrangement of module units and a central unit arranged within a housing;

[0094] Fig.10 is a top view of another arrangement of modular units and a central unit; and

[0095] Fig.11 It is a schematic diagram of a group of modular units and a central unit arranged in a spine. DETAILED DESCRIPTION

[0096] The structures disclosed herein for customizable facilities can be used to manufacture at least one product at a given time. The structures disclosed herein are particularly suitable for manufacturing a variety of products utilizing common resources.

[0097] The present disclosure provides systems and methods that allow one or more scalable product lines to be at least partially sealed within a housing of a customizable facility. Because the structure is adaptable, it does not require the user to stereotype the structure for a single product line for a long period of time. The structure can be reconfigured to meet the size requirements of the product line.

[0098] The customizable facilities of the present disclosure enable users to reduce build timelines, reduce capital expenditures, increase global design standardization, and comply with various global standards.

[0099] The customizable structure allows for a shorter turnaround time from concept to build, allows for less build site congestion, and requires fewer fixed assets when implementing new product lines.

[0100] Typically, the customizable facility includes a housing, at least one central unit located within the housing, and at least one modular unit, each modular unit being located within the housing.

[0101] Figure 1 is a top view of an exemplary embodiment of a customizable facility, generally indicated at 10 . Figure 1 The customizable facility may be constructed in a series of phases, such as a first phase 12, a second phase 14, and subsequent phases.

[0102] Installed in Figure 1 Features in the first phase 12 of construction of the customizable facility 10 include an air controlled entryway 16, a changing area 18, a utility area 20, a first manufacturing wing 22A, a first office space 24A, and at least one corridor 28 that allow occupants of the customizable facility 10 to move from one area to another within the customizable facility 10.

[0103] Outside the customizable facility 10, there is a yard 30 containing a processing area 32 for processing equipment and materials. The yard area 30 is shown adjacent to a roadway 34. In general, the customizable facility 10 can be expanded in any direction. In addition, the customizable facility 10 is constructed so that it can be expanded in a series of construction stages and / or sub-stages within the physical constraints of the surrounding features, such as the yard area 30 and the roadway 34.

[0104] Figure 1 Additional features are shown that may be added during the second phase 14 of construction, such as a second manufacturing wing 22B and a second office space 24B.

[0105] The layout of the customizable facility 10 can be configured for manufacturing in a clean room setting.The customizable facility 10 utilizes a hybrid stick or frame build building and a modular building with effect units (or utility hubs).

[0106] Reference now Figure 2A-2E , showing the relative positions of the various components of the customizable facility.

[0107] Figure 2A A perspective view of the outer wall of the outer housing 36 of the customizable facility 10 is shown. The outer housing (or housing) 36 at least partially seals the central unit (which may be a central utility unit) 38 and at least partially seals the plurality of modular units 40, as discussed further below. In some embodiments, the outer housing 36 completely seals the utility unit (which may be a central utility unit) 38 and completely seals the plurality of modular units 40.

[0108] The outer shell 36 can be constructed according to conventional stick building or another method (such as but not limited to prefabricated modules). For example, the outer shell 36 can be made of steel structure using conventional building methods. The outer shell 36 can be supported on fixed footings on the ground. The outer shell 36 is weatherproof.

[0109] The outer shell 36 forms the superstructure. In some embodiments, the outer shell 36 may be a "Butler" type building, which is known in the art of building construction.

[0110] The outer shell 36 includes side walls 42 that are sized and configured to surround one or more central units 38 and one or more modular units 40 contained in the customizable facility 10 and described in greater detail below.

[0111] A top cover 44 is secured to the upper edge of the side walls 42, and the top cover 44 extends over the central unit 38 and the modular units 40. Thus, the side walls 42 and top cover 44 seal the central unit 38 and the modular units 40 within the housing 36. The central unit 38 and the modular units 40 may be supported on the bottom surface of the housing 36 or on another support surface to which the housing is secured. The customizable facility 10 provides a partially modular (may be referred to as modular stick building) approach that includes a basic top structure that is then populated with module-type elements.

[0112] In one embodiment, Figure 2A The customizable facility 10 has an external height of 30 meters. In one embodiment, each manufacturing wing has a length of 100 meters and a width of 30 meters.

[0113] Figure 2B The exterior of the customizable facility 10 is shown in dashed lines, with the utility area being solid lines. The utility area 20 may include a central unit (which may be referred to as a Central Utility Bay (CUB) or utility building or central utility module) 38 located toward the middle of the customizable facility 10 .

[0114] Figure 1 The housing 36 also seals the future utility area 46, which is Figure 1 The future utility region 46 is adjacent to the utility module 38 and is occupied by the future utility module 38. Figure 1 . The future utility area 46 may be used as a warehouse area adjacent to the utility module 38. The future utility area 46 within this customizable facility 10 may also be suited for high bay applications, such as a 40-foot high warehouse with an automated search and retrieval system (ASARS).

[0115] In some embodiments, utility module 38 and future utility region 46 are a single utility module that is divided into a utility portion and a future utility portion.

[0116] The central utility module 38 need not be located in the center of the customizable facility 10. In some embodiments, the central utility module 38 may be located along an outer edge of the customizable facility 10.

[0117] Figure 2C The exterior of the customizable facility 10 is shown in dashed lines, with the manufacturing wings 22A, 22B being solid lines.

[0118] The manufacturing wings 22A, 22B are configured to contain modular units 40 for product lines, such as fermentation modules or purification modules. The customizable facility 10 is easily expandable and scalable, and different modular units 40 within the manufacturing wings 22A, 22B can be used to produce completely different products in the same customizable facility 10.

[0119] For example, in a module unit 40 configured as a first fermentation module, a user may manufacture one type of product, such as a monoclonal antibody product derived from a mammalian cell line. In a second module unit 40, a user may manufacture a completely different product, such as a microbial product. The customizable facility 10 of the present disclosure is capable of supporting multiple product lines and supporting multiple customers simultaneously from a single scalable superstructure. The customizable facility 10 of the present disclosure is capable of expansion to add additional product lines.

[0120] Reactors may be supported within modular units 40 of manufacturing wings 22A, 22B of the customizable facility 10. The customizable facility 10 may support any desired and suitable vessel volume. Figure 1 In some aspects shown in , the customizable facility 10 can be configured to contain production vessels of up to 20,000 liters, and storage vessels (e.g., harvest) of more than 20,000 liters (e.g., 23,000-24,000 liters). For example, the size and configuration of the customizable facility 10 can support vessels having volumes of approximately 20,000 liters, 15,000 liters, 10,000 liters, 5,000 liters, 2,000 liters, and / or 1,000 liters. Containers having other volumes can also be supported.

[0121] Any typical manufacturing and clean room equipment may be included in the customizable facility 10, and the customizable facility 10 may be fully adapted for cGMP (current good manufacturing practice) processes.

[0122] Examples of some equipment that may be adapted to the customizable facility 10 include, but are not limited to, bioreactors, disc stack centrifuges, tangential flow filtration (TFF) skids, depth filtration skids, in-line dilution skids, chromatography columns and associated control equipment, media tanks, harvest tanks, purification vessels, depth filter holders, water softening and dechlorination systems, clean steam generators, water for injection (WFI) storage tanks, WFI break tanks, WFI stills, cooling towers, switchboards, emergency generators, chillers, hydronic pumps, autoclaves, air handling units, process waste neutralization (e.g., fiberglass reinforced plastics (FRP)), biological waste collection and inactivation systems, clean-in-place systems, glass washers, and / or other equipment.

[0123] The bioreactor in the customizable facility 10 of the present disclosure can be a ground-based reactor. Alternatively, the bioreactor can be suspended from the structure itself. For example, the bioreactor can be suspended from one or more modular units 40.

[0124] The customizable facility 10 may include one or more central units 38 and one or more modular units 40. In some embodiments, each modular unit 40 is selected from the group consisting of a fermentation or cell culture unit, a pre-viral unit, a post-viral unit, a utility yard, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a filling-finished product unit, a dosage unit, and a packaging unit. The production unit may be used to manufacture products. The filling-finished product unit may be used to fill containers such as vials. The dosage unit dispenses a set dose of product. The packaging unit packages the product for distribution or sale.

[0125] The space allocated for each modular unit may be further divided as needed to suit specific processing requirements.Each manufacturing wing 22A, 22B may be configured to allow more than one modular unit 40 to be positioned within the respective manufacturing wing 22A, 22B.

[0126] exist Figure 1 and Figure 2C In the embodiment, the first manufacturing wing 22A contains three module units 40. The second manufacturing wing 22B contains two module units 40. The central utility area 20 has a length of 50 meters and a width of 20 meters and has three internal levels. The central utility block is expandable.

[0127] In some embodiments, at least one of the modular units 40 is a clean room. In some embodiments, at least one of the modular units 40 comprises a clean room portion within the respective modular unit 40.

[0128] The building shell 36 is designed to accommodate different production modules. In some embodiments, the shell can accommodate four 20,000 liter containers for mammalian cell lines. In some embodiments, the shell can accommodate four 2,000 liter containers for disposable technology operations.

[0129] In some embodiments, a manufacturing wing may comprise a modular unit containing four 20,000 liter vessels and downstream processing equipment and configured for manufacturing a monoclonal antibody product derived from a mammalian cell line, a modular unit containing disposable equipment for manufacturing a monoclonal antibody product derived from a mammalian cell line and having four 20,000 liter vessels, a modular unit configured for manufacturing a microbial product, and / or a modular unit containing disposable equipment for manufacturing a microbial product.

[0130] In one embodiment, the modular unit is configured for mammalian manufacturing and includes four 20,000 liter containers and downstream processing equipment. In another embodiment, the modular unit includes four 20,000 liter containers for commercial and clinical production. In another embodiment, the modular unit includes a 1,000 liter container for clinical production. In another embodiment, the modular unit is configured for manufacturing microbial products and includes a 15,000 liter container. In another embodiment, the modular unit includes three 5,000 liter containers. In another embodiment, the modular unit includes one or more process development laboratories. In another embodiment, the modular unit includes filling and finished clinical development vial filling equipment, one or more groups of freeze-drying equipment, equipment for manufacturing pre-filled syringes and / or equipment for manufacturing high-efficiency products for commercial applications. In some embodiments, the modular unit includes cell therapy equipment. In some embodiments, the modular unit includes virotherapy equipment.

[0131] Figure 2D The exterior of the customizable facility 10 is shown in dashed lines, with the first office space 24A and the second office space 24B shown in solid lines. The first office space 24A contains an office, a cabinet for personal storage, and a support area. The second office space 24B contains an office, a cabinet for personal storage, and a support area. The front wall 48A of the first office space 24A forms a portion of the front exterior surface of the customizable facility 10, as shown in FIG. 2. The front wall 48B of the first office space 24B forms a portion of the front exterior surface of the customizable facility 10. Therefore, each office space 24A, 24B is only partially sealed by the housing 36 of the customizable facility 10.

[0132] Similarly, in some embodiments, the outer wall of the central unit and / or the outer wall of at least one of the modular units forms at least a portion of the outer wall of the customizable facility. In some embodiments, the upper surface of the central utility module and / or the upper surface of the modular units forms a portion of the upper surface of the customizable facility.

[0133] Figure 2E The exterior of the customizable facility 10 is shown in dashed lines, with the changing area 18 being a solid line. The changing area 18 allows a user to enter the customizable facility 10 and change from casual clothes to work clothes. Figure 2E The changing area 18 in the clothing changing area 18 is further subdivided into a male changing area 18A and a female changing area 18B. In some embodiments, the changing area 18 is subdivided into two or more changing areas. In some embodiments, the changing area 18 is not subdivided.

[0134] In other embodiments, the relative positions of first and second manufacturing wings 22A, 22B, first office space 24A, second office space 24B, gowning area 18, and utility area 20 may be positioned differently within and / or oriented differently relative to customizable facility 10.

[0135] The scaffolding and corridors 28 allow users of the customizable facility 10 to access the utility units 38 and module units (fermentation, etc. modules) 40 of the utility area 20 .

[0136] After adding the second stage 14 of construction to the customizable facility 10, the user may, over time, wish to further expand the customizable facility 10. For example, consumers in the global economy may generate an increased demand for products manufactured by the user or consumers in the global economy may generate an increased demand for products that the user can produce. In response to such an increase in demand for products, the user may expand the customizable facility 10 in subsequent construction stages that add additional features to the customizable facility 10. Figure 1 In some embodiments, such additional features (such as additional modular units, additional manufacturing wings, or another component of the customizable facility) are positioned horizontally near the first manufacturing wing 22A or the second manufacturing wing 22B. In some embodiments, such additional features are positioned vertically near the first manufacturing wing 22A and / or the second manufacturing wing 22B.

[0137] Reference now Figures 3A-3E , the user can expand the manufacturing wing in different sub-stages, such as Figure 1 The user can select the first manufacturing wing 22A or the second manufacturing wing 22B. Figures 3A-3E One of the configurations shown in Figures 3A-3E Alternatively, the user can convert the manufacturing wing layout to another configuration.

[0138] Figure 3A A partially exploded view of an embodiment of a modular unit 40A is shown that is configured as a fill-finish module. Figure 3A The fill-finished product module includes a single floor 60A with a footprint of 1500 square meters. The fill-finished product module includes a mezzanine for HVAC plant rooms and some localized utilities. Freefield 50A is shown adjacent to the fill-finished product module in dotted lines and has a footprint of 1500 square meters. Freefield 50A can be used for various purposes, such as product storage. The fill-finished product module 40A and freefield 50A together extend over the 3,000 square meter footprint of the second manufacturing wing 22B.

[0139] Figure 3B A partially exploded view of an embodiment of a module unit 40B configured as a "2k module" is shown. Figure 3B The 2k module has a single floor 60B and a footprint of 1500 square meters. The 2k module can seal a 2000 liter container. The 2k module contains a middle floor for the HVAC plant room and some localized utilities. Free field 50B is shown adjacent to the 2k module in dotted lines and has a footprint of 1500 square meters. Free field 50B can be used for various purposes, such as product storage. The 2k module 40B and free field 50B together extend over the 3,000 square meter footprint of the second manufacturing wing 22B.

[0140] Figure 3C A partially exploded view of an embodiment of a module unit 40C configured as a "5k module" is shown. Figure 3C The 5k module has a single floor 60C and covers an area of ​​3,000 square meters. The 5k module can seal a 5,000 liter container. The 5k module contains a mid-level for the HVAC plant room and some localized utilities. The 5k module extends over the 3,000 square meter footprint of the manufacturing wing.

[0141] Figure 3D A partially exploded view of an embodiment of a module unit 40D configured as a "15k module" is shown. Figure 3D The 15k module has a first layer 60D and a second layer 62. Figure 3DThe 15k module has a footprint of 3,000 square meters. The 15k module can seal a 15,000 liter container. The 15k module contains a local HVAC unit, a clean-in-place (CIP) unit, and a temperature control unit (TCU). In some embodiments, the temperature control unit contains a water jacket with a heat exchanger on the tank to control the temperature of the tank used in the product line. The CIP unit is typically a module skid and has multiple tanks to hold cleaning solutions (such as caustic solutions and bleach), pumps, and sensors to deliver the cleaning solution to the appropriate tank to be cleaned.

[0142] The first layer 60D of 15k modules extends over the 3,000 square meter footprint of the manufacturing wing. The second layer 62 of 15k modules extends vertically above the first layer of 15k modules and extends over the 3,000 square meter footprint of the manufacturing wing. The first layer 60D of 15k modules and the second layer 62 of 15k modules together have a footprint of 6,000 square meters.

[0143] Figure 3E A partially exploded view of an embodiment of a module unit 40E configured as a "20k module" is shown. Figure 3E The 20k module has a footprint of 3,000 square meters. The 20k module can seal a 20,000 liter container. The 20k module contains a local HVAC unit, a CIP unit, and a TCU. The 20k module contains a first layer, a second layer, and a third layer. The first layer 60E of the 20k module extends over the 3,000 square meter footprint of the manufacturing wing. The second layer 64 of the 20k module extends vertically above the first layer 60E of the 20k module and extends over the 3,000 square meter footprint of the manufacturing wing. The third layer 66 of the 20k module extends vertically above the first layer 60E of the 20k module and the second layer 64 of the 20k module and extends over the 3,000 square meter footprint of the manufacturing wing. The first layer 60E of the 20k module, the second layer 64 of the 20k module, and the third layer 66 of the 20k module together have a combined area of ​​9,000 square meters.

[0144] Figure 4 1 is a front perspective cutaway view of an exemplary embodiment of a customizable facility, generally indicated at 110, in accordance with the present disclosure. The customizable facility 110 layout may be configured for manufacturing in a clean room setting. The customizable facility 110 utilizes a hybrid stick or frame construction building and a modular building with a centrally located utility hub (or central unit) 114.

[0145] The outer shell (or housing) 112 encloses the central unit 114 and a plurality of module units 116 adjacent to the central unit 114. The outer shell 112 can be constructed according to conventional stick building or another method (such as but not limited to prefabricated modules). For example, the outer shell 112 can be made from steel structure using conventional building methods. The outer shell 112 can be supported on fixed footings on the ground. The outer shell 112 is weatherproof.

[0146] The outer shell 112 forms the superstructure. In some embodiments, the outer shell 112 may be a "Butler" type building, which is known in the art of building construction.

[0147] The outer shell 112 includes side walls 118 that are sized and configured to surround one or more central units 114 and one or more modular units 116 contained in the customizable facility 110 and described in more detail below. A top cover 120 is secured to the upper edge of the side walls 118, and the top cover 120 extends over the central unit 114 and the modular units 116. Thus, the side walls 118 and the top cover 120 seal the central unit 114 and the modular units 116 within the shell 112. The central unit 114 and the modular units 116 may be supported on a bottom surface 122 of the shell 112 or on another support surface to which the shell 112 is secured. The customizable facility 110 provides a partially modular (which may be referred to as a modular stick build) approach that includes a basic upper structure that is then populated with module-type elements.

[0148] In the housing 112, Figure 4 The customizable facility 110 includes at least one central unit 114, each of which may be referred to as a central utility bay (CUB). The central unit 114 provides Figure 4 As shown, CUB 114 is located in the middle of a structure with modular units 116, which may be referred to as a manufacturing pod, which is derived from CUB 114 (or multiple CUBs). Figure 4 In the example, the modular unit 116 is a fermentation module. The customizable facility 110 is easily expandable and scalable, and the pod / module approach (ie, hub-and-spoke approach) allows different modules to produce completely different products in the same customizable facility 110.

[0149] For example, in the first fermentation module, such as Figure 4 In the fermentation module on the left, the user can make one type of product, such as a monoclonal antibody product derived from a mammalian cell line. In the second module, e.g. Figure 4 The fermentation module on the right side allows the user to manufacture completely different products, such as microbial products. The customizable facility 110 of the present disclosure is capable of supporting multiple product lines and multiple customers simultaneously from a single scalable superstructure.

[0150] Figure 4 A reactor 124 is shown supported within a customizable facility 110. The customizable facility 110 can support any desired and suitable container volume. For example, in a reactor such as Figure 4 In some aspects shown in . Facility 110 can be configured to contain production containers of up to 20,000 liters and storage containers (e.g., harvest) of more than 20,000 liters (e.g., 23,000-24,000 liters). For example, customizable facility 110 can be sized and configured to support container 124 having a volume of approximately 20,000 liters, 15,000 liters, 10,000 liters, 5,000 liters, 2,000 liters, and / or 1,000 liters. Containers 124 having other volumes can also be supported.

[0151] Scaffolding 126 and corridors 128 allow users of facility 110 to access central unit (central utility) 114 and modular units (fermentation, etc. modules) 116. Figure 4 As shown, the scaffold 126 is positioned within the housing 112 .

[0152] In some embodiments, one or more central units (CUBs) 114 and one or more modular units 116 are arranged in a hub-and-spoke arrangement.

[0153] Any typical manufacturing and clean room equipment may be included in the customizable facility 110, and the customizable facility 110 may be fully adapted for cGMP processes.

[0154] Examples of some of the equipment that may be installed in facility 110 include, but are not limited to: bioreactors, disc stack centrifuges, tangential flow filtration (TFF) skids, depth filtration skids, in-line dilution skids, chromatography columns and associated control equipment, media tanks, harvest tanks, purification vessels, depth filter racks, water softening and dechlorination systems, clean steam generators, water for injection (WFI) storage tanks, WFI break tanks, WFI stills, cooling towers, switchboards, emergency generators, chillers, liquid circulation heat pumps, autoclaves, air handling units, process waste neutralization (such as fiberglass reinforced plastic (FRP)), biological waste collection and inactivation systems, cleaning-in-place systems, glass washers, and / or other equipment.

[0155] like Figure 4 As shown, the bioreactor in the customizable facility 110 of the present disclosure can be a ground-based reactor. Alternatively, the bioreactor 124 can be suspended from the structure itself. For example, the bioreactor 124 can be suspended from one or more module units 116.

[0156] Figure 4The housing 112 surrounds a warehouse area 130 toward the right rear of the facility 110. The warehouse area 130 within this facility 110 can also accommodate high bay applications, such as a 40-foot high warehouse with an automated search and retrieval system (ASARS).

[0157] The customizable facility 110 may include one or more central units 114 and one or more modular units 116. In some embodiments, each modular unit 116 is selected from the group consisting of a fermentation or cell culture unit, a pre-viral unit, a post-viral unit, a utility yard, a warehouse, a media buffer facility, an office, a personnel unit, a production unit, a filling-finished product unit, a dosage unit, and a packaging unit. The space allocated to each modular unit may be further divided as needed to suit specific processing requirements.

[0158] In some embodiments, at least one of the modular units 116 is a clean room.

[0159] Figure 5 Shown is a perspective view of a set of central units 114 and modular units 116 arranged in an H-shaped configuration 132. The position of each modular unit 116 may be adjusted to best suit processing requirements.

[0160] Figure 6 and 7 An embodiment of a customizable facility is shown in which, when viewed from above, a central unit 114 and a set of eight modular units configured as purification units 116A and fermentation units 116B are arranged in an H-shaped layout 133. The housing 112 is not shown in these views. Figure 6 1 shows a plan view of a central unit (labeled Central Utility Building) 114 having a first row of modular units configured as purification units 116A and fermentation units 116B arranged in a linear array 134 adjacent to a first side 136 of the central unit 114 and a second row of modular units configured as purification units 116A and fermentation units 116B arranged in a linear array 138 adjacent to a second side 140 of the central unit 114. The array 134 of modular units includes four modular units, a first purification unit 116A at a first end of the array 134, two fermentation units 116B in the middle of the array 134, and a second purification unit 116A at a second end of the array 134. Similarly, the array 138 of modular units includes four modular units, a first purification unit 116A at a first end of the array 138, two fermentation units 116B in the middle of the array 138, and a second purification unit 116A at a second end of the array 138.

[0161] Each of the two fermentation units 116B of the first array 134 of modular units includes a side wall that directly faces the first side wall 136 of the central unit 114. Similarly, each of the two fermentation units 116B of the second array 138 of modular units includes a side wall that directly faces the second side wall 140 of the central unit 114. The purification units 116A are in a directly facing relationship with their respective adjacent fermentation units 116B. Due to the direct facing engagement of the central unit 114 and the fermentation unit 116B, the number of central units 114 and modular units that can be assembled in a given size of the housing 112 is increased. Likewise, the footprint of the housing 112 required to seal a given set of central units 114 and modular units is reduced. Optionally, in some aspects, the side walls of the fermentation units 116B (or other modular units) do not need to directly face the engagement, but can be spaced to provide any desired footprint.

[0162] The modular units 116 and the central unit 114 can be arranged to facilitate the simultaneous manufacture of multiple products. The modular units 116 and the central unit 114 are arranged to effectively share resources between production lines of corresponding products. For example, in some embodiments, the central unit 114 contains at least one of the following: a generator, a plumbing line, a power line, and other resources that can be shared by the modular units 116. In addition, the modular units 116 and the central unit 114 can be arranged to facilitate future expansion of manufacturing capabilities. For example, a single modular unit 116 can be utilized initially, and additional modular units 116 can be added at a later time with minimal impact on existing operations.

[0163] In some embodiments, each modular unit 116 contains its own respective heating, ventilation, and air conditioning (HVAC) system, as required for operation and isolation.

[0164] In some embodiments, the spoke arrangement may resemble the letter H, such as in Figure 6 In other embodiments, the spoke arrangement does not resemble the letter H. Other shapes are possible, including but not limited to: squares, rectangles, pentagons, and other geometric shapes, as long as it has a central unit (central utility compartment) with at least one modular unit extending therefrom. Other shapes are also possible, for example, Fig.10 In some embodiments, for example, a linear "spine" shape may be used or an "E" shape may be used such that the hub-and-spoke arrangement resembles the letter E.

[0165] In some embodiments, the central unit 114 is not at the center of the arrangement of the central unit 114 and the modular units 116. The arrangement of the modular units 116 and the central unit 114 is preferably configured to reduce the number of modular units 116 required for a given set of production lines.

[0166] The modular units 116 may be separated from one another to reduce cross contamination of products or kits.

[0167] Figure 8 A plan view of another preferred embodiment of a customizable facility 1000 of the present disclosure is shown. Two central units 114 face Figure 8 The bottom center of the plan view of the structure shown is located between the common corridors 128 that extend along the walls of the central unit 114. To the left of the central unit 114 is a grouping of six modular units. This grouping includes two pre-viral units 116C, two post-viral units 116D, and two fermentation units 116B. Figure 8 To the right of the central unit 114 is shown a grouping of six modular units, including two pre-viral units 116C, two post-viral units 116D, and two fermentation units 116B. This configuration is designed to be expanded with additional capacity as needed (e.g., see Fig.10 As an example of an implementation scheme for displaying expansion options). Figure 8 At the top of the facility 1000 shown, there are other modular units, including a utility unit 116E, two warehouse units 116F, two media / buffer facility units 116G and an office unit 116H, and two personnel access units 116J. Not shown in this figure is the ability to add separate buffer holding modular units directly above each purification unit. A common corridor 128 runs along the wall of the unit so that users can access the common corridor 128. Figure 8 each module unit and the central unit 114.

[0168] Different units can have different classification levels according to the rating criteria. For example, according to the classification criteria established by the US Food and Drug Administration or the classification criteria established by EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use (supplemented by Annex 1 Manufacture of Sterile Medicinal Products in the European Union), different units can have different classification levels. For example, according to the EU standard, Figure 8 The pre-viral unit 116C, post-viral unit 116D and culture medium / buffer facility unit 116G in the fermentation unit are classified as "Class C", while the fermentation unit 116B is classified as "Class D", and the remaining units are unclassified. Other classifications of units are possible and can be selected according to user needs.

[0169] Fig. 9 Another embodiment of a customizable facility 1200 of the present disclosure is shown. Fig. 9 Contains a central unit (central utility building) 114 with corridors 128 for cleaning materials and personnel on either side of the central unit 114. The corridors 128 are connected to the Fig. 9 The warehouse 116F at the upper end of the facility 1200 is shown extending beyond the central unit 114 at the bottom of the facility. Outside of the corresponding corridors 128 are the locker room unit 116K, the pre-viral unit 116C, the post-viral unit 116D and the fermentation unit 116B.

[0170] In one embodiment, such as Fig. 9 In the embodiment shown in FIG. 1 , each fermentation unit 116B has dimensions of 63 feet by 65 feet and is 35 feet high. In one embodiment, in a Fig. 9 In the embodiment shown in , the pre-viral unit 116C may have dimensions of 62 feet by 50 feet and be 17 feet high. In one embodiment. Fig. 9 In the embodiment shown, the post-viral units 116D each have dimensions of 62 feet by 65 feet and are 35 feet tall. In other embodiments, the units may have other dimensions.

[0171] Fig.10 Another embodiment of a customizable facility 1300 of the present disclosure is shown in which the housing 112 is not shown. Fig.10 Contains the five elements area. Fig.10 The first row (top row) 142 in the plan view of FIG. 1 comprises purification area 117A. The second row 144 comprises fermentation area 117B. The third row 150 comprises central utility area 114. The fourth row 146 comprises fermentation area 117B. The fifth row 148 comprises purification area 117A.

[0172] In some aspects, a customizable facility for manufacturing at least one pharmaceutical product may include at least one central unit and at least one modular unit, but the customizable facility does not include a housing. Each modular unit communicates with at least one central unit such that at least one central unit provides utility to each modular unit.

[0173] The solid line areas represent a set of areas that may be provided in an initial configuration. In this initial configuration 160, there are three purification areas (PURE 1, PURE 3, PURE 5) 117A in the first row 142, three fermentation areas (FERM 1, FERM 3, FERM 5) 117B in the second row 144, a central utility area (Central Utility 1) 115 in the third row 150, three fermentation areas (FERM 2, FERM 4, FERM 6) 117B in the fourth row 146, and three purification areas (PURE 2, PURE 4, PURE 6) 117A in the fifth row 148.

[0174] A set of zones 162 may be added by expanding the zone array to the right. For example, two additional purification zones (PURE 7, PURE 9) 117A may be added to the first row 142, two additional fermentation zones (FERM 7, FERM 9) 117B may be added to the second row 144; an additional central utility zone 114 may be added to the third row 150, two additional fermentation zones (FERM 8, FERM 10) 117B may be added to the fourth row 146, and two additional purification zones (PURE 8, PURE 10) 117A may be added to the fifth row 148. Arrows to the right, such as arrow A between fermentation zones 117B labeled FERM 9 and FERM N+1, indicate potential directions of expansion of the zone array. Additional zones may be added to the respective rows as needed, and Fig.10Shown are a purification unit (PURE N+1) 117 at the end of the first row 142, a fermentation zone (FERM N+1) 117B at the end of the second row 144, a fermentation zone (FERM N) 117B in the direction of arrow B at the end of the fourth row 146, and a purification zone (PURE N) 117A at the end of the fifth row 148. The N value may be an integer value selected by the user as desired and is limited only by the internal dimensions of the housing 112 within which the modular units 116 and the central unit 114 are located.

[0175] The third row may be expanded by adding the central utility area 114 to the third row 150 along arrow C.

[0176] Fig.10 The areas are areas that can each be a central unit or a modular unit (e.g., a fermentation unit, a purification unit, etc.), or areas that can support equipment for the unit. Fig.10 Where a region is shown, for example region FERM 1, this region may be subdivided into a fermentation unit FERM 1 and one or more corridors within the region. In at least some regions, a unit may occupy the entire region.

[0177] The modular units 116 disclosed herein can be further subdivided into subunits. For example, a unit can have a pre-viral subunit and a post-viral subunit. The post-viral subunit is virus-free.

[0178] At once Figure 4-9 For purposes of the present invention, although the figures show a view divided into areas described as units, the areas of the view may specify regions (such as a purification area, a fermentation area, etc.), each of which contains units and one or more corridors connecting the units.

[0179] Fig.11 Another exemplary embodiment of a facility 1400 is shown in which the central unit 114 is in the shape of a linear "spine" from which emanates a plurality of modules 116. In this embodiment, the modules 116 can be subsequently added in multiple construction phases, allowing the facility to expand over time.

[0180] According to one aspect of the present disclosure, a method of assembling a facility for manufacturing at least one pharmaceutical product may include providing a housing, positioning at least one central unit at least partially within the housing, and positioning at least one modular unit at least partially within the housing.

[0181] Example of a fermentation unit

[0182] Fermentation unit 116B contains equipment suitable for cell culture and / or fermentation. For example, equipment for cell culture and fermentation includes, but is not limited to, bioreactors (e.g., suitable for culturing cells or fermentation), tanks (e.g., suitable for containing cells, culture medium, or products produced by cells), decanters, centrifuges, pumps, and other equipment that can be used for product recovery. Refold tanks and microfiltration units are included for microbial fermentation processes.

[0183] In one embodiment, fermentation unit 116B contains one or more bioreactor units suitable for cultured cells. Bioreactor unit can carry out following one or more or all: the flow of the feeding of nutrients and / or carbon source, the injection of suitable gas (e.g., oxygen), fermentation or cell culture medium, the separation of gas phase and liquid phase, the maintenance of growth temperature, the maintenance of pH level, stirring (e.g., agitation) and / or cleaning / sterilization. Fermentation unit can contain 1,2,3,4,5,10,15,20,25,30,35,40,45,50,60,70,80,90 or 100 or more bioreactors. In various embodiments, bioreactor is suitable for batch, semi-fed-batch, fed-batch, perfusion and / or continuous fermentation process. In one embodiment, bioreactor is a stirred tank reactor. In one embodiment, bioreactor is an airlift reactor. In one embodiment, bioreactor can have a volume of about 100 milliliters to about 50,000 liters. Non-limiting examples include 100 ml, 250 ml, 500 ml, 750 ml, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, 40 liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, A volume of 600 liters, 650 liters, 700 liters, 750 liters, 800 liters, 850 liters, 900 liters, 950 liters, 1000 liters, 1500 liters, 2000 liters, 2500 liters, 3000 liters, 3500 liters, 4000 liters, 4500 liters, 5000 liters, 6000 liters, 7000 liters, 8000 liters, 9000 liters, 10,000 liters, 15,000 liters, 20,000 liters, or 50,000 liters.

[0184] In one embodiment, the bioreactor is suitable for culturing suspension cells or anchorage-dependent (adherent) cells. In one embodiment, the fermentation kit is suitable for cell therapy and / or viral therapy operations. In one embodiment, the bioreactor is suitable for culturing prokaryotic cells or eukaryotic cells. Examples of cells include, but are not limited to, bacterial cells (e.g., Escherichia coli (E. coli), Pichia pastoris (P. pastoris)), yeast cells (e.g., Saccharomyces cerevisiae (S. cerevisiae), Trichoderma reesei (T. reesei)), plant cells, insect cells (e.g., Sf9), Chinese hamster ovary cells (CHO, and any genetically modified or derived CHO cell lines), mouse cells (e.g., mouse embryonic fibroblasts, cells derived from mouse cancer models), human cells (e.g., cells from any tissue or organ, cells from cancer or other diseased cell lines, stem cells), hybridoma cells or other genetically modified or hybrid cells. In one embodiment, the cell expresses or produces a product, such as a recombinant therapeutic or diagnostic product. Examples of products produced by cells include, but are not limited to, antibody molecules (e.g., monoclonal antibodies, bispecific antibodies), fusion proteins (e.g., Fc fusion proteins, chimeric cytokines), other recombinant proteins (e.g., glycosylated proteins, enzymes, hormones), or lipid-encapsulated particles (e.g., exosomes, virus-like particles). In embodiments, the fermentation unit further comprises equipment for separating, purifying, and isolating such products from the cells. In one embodiment, the facility and / or bioreactor can be used to produce a biosimilar product.

[0185] In an embodiment, the fermentation unit complies with good manufacturing processes and biosafety standards. In an embodiment, the fermentation unit complies with biosafety level 1 (BSL1), biosafety level 2 (BSL2), biosafety level 3 (BSL3), or biosafety level 4 (BSL4).

[0186] The fermentation unit may comprise sub-compartments, wherein each sub-compartment may be used to perform a different function or aspect of supporting the cell culture, fermentation and production process. For example, a fermentation unit comprises a sub-compartment housing one or more bioreactors, a sub-compartment housing product recovery equipment, a sub-compartment for inoculation, and a sub-compartment for cleaning and decontamination equipment and operators handling such equipment.

[0187] Instances of downstream processing units

[0188] Purification unit 116A discussed above is an example of a downstream processing unit.

[0189] As an example, a standard downstream processing (DSP) unit comprises a pre-viral separation and a post-viral separation subunit. Although viral reduction does occur throughout typical mammalian cell derived protein purification, it is believed that the critical viral reduction step is an appropriate point of spatial separation from the post-viral separation subunit, which should be considered substantially virus-free. The post-viral separation subunit houses equipment and utilities suitable for any of the following: ultrafiltration (tangential filtration), normal filtration, chromatography, formulation, titration, mixing, concentration, buffer exchange, bulk drug substance container filling and freezing.

[0190] The description of various embodiments and / or examples of the present disclosure has been presented for the purpose of illustration, but is not intended to be exhaustive or limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The terms used herein are selected to best explain the principles of the embodiments, practical applications, or technical improvements to technologies found in the marketplace, or to enable those of ordinary skill in the art to understand the embodiments disclosed herein.

[0191] The description of various embodiments of the present disclosure can be used to produce drugs and biopharmaceutical products. The devices, facilities and methods described herein are suitable for cultivating any desired cell line, including prokaryotic and / or eukaryotic cell lines. In addition, in embodiments, the devices, facilities and methods are suitable for cultivating suspension cells or anchorage-dependent (adherent) cells, and are suitable for configuration for the production of drugs and biopharmaceutical products, such as polypeptide products, nucleic acid products (e.g., DNA or RNA), or cells and / or viruses, such as production operations of cells and / or viruses for cell and / or virus therapy.

[0192] In embodiments, cells express or produce products, such as recombinant therapeutic or diagnostic products. As described in more detail below, examples of products produced by cells include, but are not limited to, antibody molecules (e.g., monoclonal antibodies, bispecific antibodies), antibody mimics (polypeptide molecules that specifically bind to antigens but are structurally unrelated to antibodies, such as DARPins, affibodies, adnectins, or IgNARs), fusion proteins (e.g., Fc fusion proteins, chimeric cytokines), other recombinant proteins (e.g., glycosylated proteins, enzymes, hormones), viral therapeutics (e.g., anticancer oncolytic viruses, viral vectors for gene therapy, and viral immunotherapy), cell therapies (e.g., pluripotent stem cells, mesenchymal stem cells, and adult stem cells), vaccines or lipid-encapsulated particles (e.g., exosomes, virus-like particles), RNA (e.g., siRNA) or DNA (e.g., plasmid DNA), antibiotics, or amino acids. In embodiments, devices, facilities, and methods can be used to produce biosimilars.

[0193] As mentioned, in embodiments, the apparatus, facilities and methods allow for the production of eukaryotic cells, such as mammalian cells or lower eukaryotic cells, such as yeast cells or filamentous fungal cells, or prokaryotic cells, such as Gram-positive cells or Gram-negative cells and / or the production of eukaryotic cells or prokaryotic cells, such as proteins, peptides, antibiotics, amino acids, nucleic acids (such as DNA or RNA), which are synthesized by eukaryotic cells in a large-scale manner. Unless otherwise specified herein, the apparatus, facilities and methods can comprise any desired volume or production capacity, including but not limited to laboratory scale, pilot scale and full production scale capabilities.

[0194] In addition, unless otherwise specified herein, the apparatus, facilities and methods may include any suitable reactor, including but not limited to stirred tanks, airlifts, fibers, microfibers, hollow fibers, ceramic matrices, fluidized beds, fixed beds and / or spouted bed bioreactors. As used herein, a "reactor" may include a fermentor or fermentation unit, or any other reaction vessel, and the term "reactor" may be used interchangeably with a "fermentor." For example, in some aspects, an exemplary bioreactor unit may perform one or more or all of the following: feeding of nutrients and / or carbon sources, injection of a suitable gas (e.g., oxygen), inlet and outlet flows of a fermentation or cell culture medium, separation of gas and liquid phases, maintenance of temperature, maintenance of oxygen and CO2 levels, maintenance of pH levels, stirring (e.g., agitation) and / or cleaning / disinfection. Exemplary reactor unit such as fermentation unit can comprise multiple reactors in unit, for example unit can have 1,2,3,4,5,10,15,20,25,30,35,40,45,50,60,70,80,90 or 100 or more bioreactors and / or facilities in each unit can contain multiple units with single or multiple reactors in the facilities.In various embodiments, bioreactor can be suitable for batch, semi-fed-batch, fed-batch, perfusion and / or continuous fermentation process.Can use any suitable reactor diameter.In embodiments, bioreactor can have the volume of about 100mL to about 50,000L. Non-limiting examples include 100 ml, 250 ml, 500 ml, 750 ml, 1 liter, 2 liters, 3 liters, 4 liters, 5 liters, 6 liters, 7 liters, 8 liters, 9 liters, 10 liters, 15 liters, 20 liters, 25 liters, 30 liters, 40 liters, 50 liters, 60 liters, 70 liters, 80 liters, 90 liters, 100 liters, 150 liters, 200 liters, 250 liters, 300 liters, 350 liters, 400 liters, 450 liters, 500 liters, 550 liters, 6 1,000 liters, 15,000 liters, 20,000 liters, and / or 50,000 liters. In addition, suitable reactors can be multiple use, single use, disposable or non-disposable, and can be formed of any suitable material, including metal alloys, such as stainless steel (e.g., 316L or any other suitable stainless steel) and Inconel, plastics and / or glass.

[0195] In embodiments and unless otherwise specified herein, the devices, facilities and methods described herein may also include any suitable unit operations and / or equipment not otherwise mentioned, such as operations and / or equipment for separating, purifying and separating such products. Any suitable facilities and environments may be used, such as traditional rod-type building facilities, modules, mobile and temporary facilities, or any other suitable structures, facilities and / or layouts. For example, in some embodiments, a module clean room may be used. Additionally and unless otherwise specified, the devices, systems and methods described herein may be accommodated and / or performed in a single location or facility, or alternatively accommodated and / or performed in separate or multiple locations and / or facilities.

[0196] By way of non-limiting example and not limitation, U.S. Publication Nos. 2013 / 0280797; 2012 / 0077429; 2011 / 0280797; 2009 / 0305626; and U.S. Patent Nos. 8,298,054; 7,629,167; and 5,656,491 (which are hereby incorporated by reference in their entireties) describe exemplary facilities, devices, and / or systems that may be suitable.

[0197] In embodiments, the cell is a eukaryotic cell, such as a mammalian cell. The mammalian cell can be, for example, a human or rodent or bovine cell line or cell strain. Examples of such cells, cell lines or cell strains are, for example, mouse myeloma (NSO) cell lines, Chinese hamster ovary (CHO) cell lines, HT1080, H9, HepG2, MCF7, MDBK Jurkat, NIH3T3, PC12, BHK (baby hamster kidney cells), VERO, SP2 / 0, YB2 / 0, Y0, C127, L cells, COS (e.g., COS1 and COS7), QC1-3, HEK-293, VERO, PER.C6, HeLA, EB1, EB2, EB3, oncolytic or hybridoma cell lines. Preferably, the mammalian cell is a CHO cell line. In one embodiment, the cell is a CHO cell. In one embodiment, the cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHO FUT8 GS knockout cell, a CHOZN, or a CHO-derived cell. A CHO GS knockout cell (e.g., a GSKO cell) is, for example, a CHO-K1 SV GS knockout cell. A CHO FUT8 knockout cell is, for example, CHOK1 SV (Lonza Biologics, Inc.). The eukaryotic cell may also be an avian cell, cell line or cell strain, such as cells, EB14, EB24, EB26, EB66 or EBv13.

[0198] In one embodiment, the eukaryotic cell is a stem cell. The stem cell can be, for example, a pluripotent stem cell, including embryonic stem cells (ESC), adult stem cells, induced pluripotent stem cells (iPSC), tissue-specific stem cells (eg, hematopoietic stem cells) and mesenchymal stem cells (MSC).

[0199] In one embodiment, the cell is a differentiated form of any cell described herein. In one embodiment, the cell is a cell derived from any primary cell in culture.

[0200] In an embodiment, the cell is a hepatocyte, such as a human hepatocyte, an animal hepatocyte, or a non-parenchymal cell. For example, the cell can be a plateable metabolism qualified human hepatocyte, a plateable induction qualified human hepatocyte, a plateable Qualyst Transporter Certified TM Human hepatocytes, suspension qualified human hepatocytes (including 10 donors and 20 donors pooled hepatocytes), human liver Kupffer cells, human hepatic stellate cells, dog hepatocytes (including single and pooled Beagle hepatocytes), mouse hepatocytes (including CD-1 and C57BI / 6 hepatocytes), rat hepatocytes (including Sprague-Dawley, Wistar Han and Wistar hepatocytes), monkey hepatocytes (including Cynomolgus or Rhesus hepatocytes), cat hepatocytes (including Domestic Shorthair hepatocytes) and rabbit hepatocytes (including New Zealand White hepatocytes). Exemplary hepatocytes can be purchased from Triangle Research Labs, LLC, 6 Davis Drive Research Triangle Park, North Carolina, USA 27709.

[0201] In one embodiment, the eukaryotic cell is a lower eukaryotic cell, such as, for example, a yeast cell (e.g., a Pichia genus (e.g., Pichia pastoris, Pichia methanolica, Pichia kluyveri, and Pichia angusta), a Komagataella genus (e.g., Komagataella pastoris, Komagataellapseudopastoris, or Komagataella phaffii), a Saccharomyces genus (e.g., Saccharomyces cerevisae, Saccharomyces cerevisiae, Saccharomyces kluyveri, Saccharomyces uvarum), a Kluyveromyces genus (e.g., Kluyveromyces lactis, Kluyveromyces marxianus), a Candida genus (e.g., Candida utilis), a utilis), Candida cacaoi, Candida boidinii), Geotrichum (e.g., Geotrichumfermentans), Hansenula polymorpha, Yarrowia lipolytica or Schizosaccharomyces pombe. Pichia pastoris is preferred. Examples of Pichia pastoris strains are X33, GS115, KM71, KM71H; and CBS7435.

[0202] In one embodiment, the eukaryotic cell is a fungal cell (e.g., Aspergillus (e.g., A. niger, A. fumigates, A. orzyae, A. nidula), Acremonium (e.g., A. thermophilum), Chaetomium (e.g., C. thermophilum), Chrysosporium (e.g., C. thermophile), Cordyceps (e.g., C. militaris), Corynascus, Ctenomyces, Fusarium (e.g., F. oxysporum), Glomerella (e.g., G. graminis), cola), Hypocrea (e.g., H. jecorina), Magnaporthe (e.g., M. orzyae), Myceliophthora (e.g., M. thermophile), Nectria (e.g., N. heamatococca), Neurospora (e.g., N. crassa), Penicillium, Sporotrichum (e.g., S. thermophile), Thielavia (e.g., T. terrestris, T. heterothallica), Trichoderma (e.g., T. reesei), or Verticillium (e.g., V. dahlia).

[0203] In one embodiment, the eukaryotic cell is an insect cell (e.g., Sf9, Mimic TM Sf9, Sf21, HighFive TMThe invention can be used in conjunction with a plant cell, such as a cell from a monocotyledonous plant, such as corn, rice, wheat, or Setaria, or a cell from a dicotyledonous plant, such as a cell from cassava, potato, soybean, tomato, tobacco, alfalfa, Physcomitrella patens, or Arabidopsis.

[0204] In one embodiment, the cell is a bacteria or a prokaryotic cell.

[0205] In embodiments, the prokaryotic cell is a gram-positive cell, such as Bacillus, Streptomyces, Streptococcus, Staphylococcus, or Lactobacillus. Bacillus that can be used is, for example, Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus licheniformis, Bacillus natto, or Bacillus megaterium. In embodiments, the cell is Bacillus subtilis, such as Bacillus subtilis 3NA and Bacillus subtilis 168. Bacillus can be obtained from, for example, the Bacillus Genetic Stock Center, Biological Sciences 556, 484 West 12 th Avenue, Columbus OH 43210-1214.

[0206] In one embodiment, the prokaryotic cell is a Gram-negative cell, such as a Salmonella species or E. coli, such as TG1, TG2, W3110, DH1, DHB4, DH5a, HMS174, HMS174 (DE3), NM533, C600, HB101, JM109, MC4100, XL1-Blue and Origami, as well as those derived from E. coli B-strains, such as, for example, BL-21 or BL21 (DE3), all of which are commercially available.

[0207] Suitable host cells can be purchased, for example, from culture collections, such as DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany) or the American Type Culture Collection (ATCC).

[0208] In embodiments, the cultured cells are used to produce proteins for therapeutic use, such as antibodies, such as monoclonal antibodies and / or recombinant proteins. In embodiments, the cultured cells produce peptides, amino acids, fatty acids or other useful biochemical intermediates or metabolites. For example, in embodiments, molecules having a molecular weight of about 4000 Daltons to greater than about 140,000 Daltons can be prepared. In embodiments, these molecules can have a range of complexity and can include post-translational modifications, including glycosylation.

[0209] In embodiments, the protein is, for example, BOTOX, Myobloc, Neurobloc, Dysport (or other botulinum neurotoxin serotypes), alglucosidase alfa, daptomycin, YH-16, chorionic gonadotropin alfa, filgrastim, cetrorelix, interleukin-2, aldesleukin, teceleulin, denileukin 2, diftitox), interferon alpha-n3 (injection), interferon alpha-nl, DL-8234, interferon, Suntory (gamma-1a), interferon gamma, thymosin alpha 1, tasonermin, DigiFab, ViperaTAb, EchiTAb, CroFab, nesiritide, abatacept, alefacept, Rebif, eptoterminalfa, teriparatide (osteoporosis), calcitonin injection (bone disease), calcitonin (nasal, osteoporosis), etanercept, hemoglobin glutamer 250 (cow), drotrecogin alpha, collagenase, carperitide, recombinant human epidermal growth factor (topical gel, wound healing), DWP401,Darbepoetin alpha, epoetin omega, epoetin beta, epoetin alpha, desirudin, lepirudin, bivalirudin, nonacog alpha, mononine, eptacog alpha (activated), recombinant factor VIII + VWF, recombinate, recombinant factor VIII, factor VIII (recombinant), Alphnmate, octocog alpha alpha), factor VIII, palifermin, indikinase, tenecteplase, alteplase, pamiteplase, reteplase, nateplase, monteplase, follitropin alpha, rFSH, hpFSH, micafungin, pegfilgrastim, lenograstim, nartograstim, sermorelin, glucagon, exenatide, pramlintide, iniglucerase, galsulfase, leucotropin, molgramostirn, triptorelin acetate acetate), histrelin (subcutaneous implant, Hydron), deslorelin, histrelin, nafarelin, leuprolide sustained-release reservoir (ATRIGEL), leuprolide implant (DUROS), goserelin, Eutropin, KP-102 program, growth hormone, mecasermin (growth failure), enlfavirtide, Org-33408, insulin glargine, insulin glulisine, insulin (inhaled), insulin lispro, insulin deternir, insulin (oral,RapidMist), mecasermin rinfabate, anakinra, celmoleukin, 99mTc-apcitide injection, myelopid, recombinant interferon beta-1b (Betaseron), glatiramer acetate, Gepon, sargramostim, oprelvekin, human leukocyte-derived interferon alpha, Bilive, insulin (recombinant), recombinant human insulin, insulin aspart, mecasenin, Roferon-A, interferon-alpha 2, Alfaferone, interferon alfacon-1, interferon alpha, Avonex recombinant human luteinizing hormone, dornase alpha alpha), trafermin, ziconotide, taltirelin, diboterminalfa, atosiban, becaplermin, eptifibatide, Zemaira, CTC-111, Shanvac-B, HPV vaccine (quadrivalent), octreotide, lanreotide, ancestirn, agalsidase beta, agalsidase alpha, laronidase, prezatide copper acetate (topical gel), rasburicase, ranibizumab, interferon gamma-1b (Actimmune), PEG-Intron, Tricomin, recombinant house dust mite allergy desensitization injection, recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), epoetin delta, transgenic antithrombin III, Granditropin, hyaluronidase (Vitrase), recombinant insulin, interferon-alpha (oral tablet), GEM-21S, vapreotide, idursulfase, omnapatrilat, recombinant serum albumin, certolizumab pegol, glucarpidase, human recombinant C1 esterase inhibitor (angioedema), lanoteplase, recombinant human growth hormone, enfuvirtide (needle-free injection,Biojector2000), VGV-1, interferon (α), lucinactant, aviptadil (inhalation, lung disease), icatibant, ecallantide, omiganan, Aurograb, pexiganan acetate, ADI-PEG-20, LDI-200, degarelix, cintredelinbesudotox, Favld, MDX-1379, ISAtx-247, liraglutide, teriparatide (osteoporosis), tifacogin, AA4500, T4N5 liposome lotion, catumaxomab, DWP413, ART-123, Ch rysalin, desmoteplase, amediplase, corifollitropin alpha, TH-9507, teduglutide, Diamyd, DWP-412, growth hormone (sustained release injection), recombinant G-CSF, insulin (inhaled, AIR), insulin (inhaled, Technosphere), insulin (inhaled, AERx), RGN-303, DiaPep277, interferon beta (hepatitis C virus infection (HCV)), interferon alpha-n3 (oral), belatacept, transdermal insulin patch, AMG-531, MBP-8298, Xerecept, opebacan, AIDSVAX, GV-1001, LymphoScan, ranpirnase, Lipoxysan, lusupultide, MP52 (beta-tricalcium phosphate carrier, bone regeneration), melanoma vaccine, sipuleucel -T, CTP-37, Insegia, vitespen, human thrombin (freezing, surgical bleeding), thrombin, TransMID, alfimeprase, Puricase, terlipressin (intravenous, hepatorenal syndrome), EUR-1008M, recombinant FGF-I (injectable, vascular disease), BDM-E, rotigaptide, ETC-216, P-113, MBI-594AN, duramycin (inhalation,Cystic fibrosis), SCV-07, OPI-45, Endostatin, Angiostatin, ABT-510, Bowman Birk inhibitor concentrate, XMP-629, 99mTc-Hynic-Annexin V, kahalalide F, CTCE-9908, teverelix (extended release), ozarelix, romidepsin, BAY-504798, interleukin-4, PRX-321, Pepscan, iboctadekin, rhlactoferrin, TRU-015, IL-21, ATN-161, cilengitide, Albuferon, Biphasix, IRX-2, omega interferon, PCK-3145, CAP-232, pasireotide, huN901-DMI, ovarian cancer immunotherapy vaccine, SB-249553, Oncovax-CL, OncoVax-P, BLP-25, CerVax-16, multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), nemifi tide), rAAT (inhaled), rAAT (dermatology), CGRP (inhaled, asthma), pegsunercept, thymosin beta 4, plitidepsin, GTP-200, ramoplanin, GRASPA, OBI-1, AC-100, salmon calcitonin (oral, eligen), calcitonin (oral, osteoporosis), examorelin, capromorelin, Cardeva, velafermin, 131I-TM-601, KK-220, T-10, ularitide, depelestat, hematide, Chrysalin (topical), rNAPc2, recombinant factor V111 (PEGylated liposome), bFGF, PEGylated recombinant staphylokinase variant, V-10153, SonoLysis Prolyse, NeuroVax, CZEN-002, pancreatic islet cell regeneration therapy, rGLP-1, BIM-51077, LY-548806, exenatide (controlled release,Medisorb), AVE-0010, GA-GCB, avorelin, ACM-9604, linaclotide acetate, CETi-1, Hemospan, VAL (injection), rapid-acting insulin (injection, Viadel), intranasal insulin, insulin (inhalation), insulin (oral, eligen), recombinant human leptin, pitrakinra subcutaneous injection, eczema), pitrakinra (inhalation dry powder, asthma), Multikine, RG-1068, MM-093, NBI-6024, AT-001, PI-0824, Org-39141, Cpn10 (autoimmune disease / inflammation), talactoferrin (topical), rEV-131 (ophthalmology), rEV-131 (respiratory disease), oral recombinant human insulin (diabetes), RPI-78M, oprelvekin (oprelvekin) (oral), CYT-99007CTLA4-Ig, DTY-001, valategrast, interferon alpha-n3 (topical), IRX-3, RDP-58, Tauferon, bile salt-stimulated lipase, merispase, alalinephosphatase, EP-2104R, Melanotan-II, bremelanotide, ATL-104, recombinant human microplasmin, AX-200, SEMAX, ACV-1, Xen-2174, CJC-1008, dynorphin A, SI-6603, LAB GHRH, AER-002, BGC-728, malaria vaccine (virion, PeviPRO), ALTU-135, parvovirus B19 vaccine, influenza vaccine (recombinant neuraminidase), malaria / HBV vaccine, anthrax vaccine, Vacc-5q, Vacc-4x, HIV vaccine (oral), HPV vaccine, Tat toxoid, YSPSL, CHS-13340, PTH (1-34) liposome cream (Novasome), Ostabolin-C, PTH analog (topical, psoriasis),MBRI-93.02, MTB72F vaccine (tuberculosis), MVA-Ag85A vaccine (tuberculosis), FARA04, BA-210, recombinant plague FIV vaccine, AG-702, OxSODrol, rBetV1, Der-p1 / Der-p2 / Der-p7 allergen targeted vaccine (dust mite allergy), PR1 peptide antigen (leukemia), mutant ras vaccine, HPV-16E7 lipopeptide vaccine, labyrinth vaccine ( vaccine) (adenocarcinoma), CML vaccine, WT1-peptide vaccine (cancer), IDD-5, CDX-110, Pentrys, Norelin, CytoFab, P-9808, VT-111, icrocaptide, telbermin (skin disease, diabetic foot ulcer), rupintrivir, reticulose, rGRF, HA, α-galactosidase A, ACE-011, ALTU-140, CGX-1160, angiotensin II Zhangsu therapeutic vaccine, D-4F, ETC-642, APP-018, rhMBL, SCV-07 (oral, tuberculosis), DRF-7295, ABT-828, ErbB2-specific immunotoxin (anti-cancer), DT3SSIL-3, TST-10088, PRO-1762, Combotox, cholecystokinin-B / gastrin receptor binding peptide, 111In-hEGF, AE-37, trasnizumab-DM1, antagonist G, IL-12 (recombinant), PM-02 734, IMP-321, rhIGF-BP3, BLX-883, CUV-1647 (topical), L-19-based radioimmunotherapy (cancer), Re-188-P-2045, AMG-386, DC / 1540 / KLH vaccine (cancer), VX-001, AVE-9633, AC-9301, NY-ESO-1 vaccine (peptide), NA17.A2 peptide, melanoma vaccine (pulse antigen therapy), prostate cancer vaccine, CBP-501, recombinant human lactoferrin (dry eye), F X-06, AP-214, WAP-8294A (injectable), ACP-HIP, SUN-11031, peptide YY [3-36] (obesity, intranasal), FGLL, atacicept, BR3-Fc, BN-003, BA-058, human parathyroid hormone 1-34 (nasal, osteoporosis), F-18-CCR1, AT-1100 (celiac disease / diabetes), JPD-003, PTH (7-34) liposome cream (Novasome), duramycin (ophthalmic,dry eye), CAB-2, CTCE-0214, GlycoPEGylated erythropoietin, EPO-Fc, CNTO-528, AMG-114, JR-013, Factor XIII, aminocandin, PN-951, 716155, SUN-E7001, TH-0318, BAY-73-7977, teverelix (immediate release), EP-51216, hGH (controlled release, Biosphere), OGP-I, sifuvirtide, TV4710, ALG-889, Org-41259, rhCC10, F-991, thymopentin (t hymopentin (lung disease), r(m)CRP, liver-selective insulin, subalin, L19-IL-2 fusion protein, elafin, NMK-150, ALTU-139, EN-122004, rhTPO, thrombopoietin receptor agonist (thrombocytopenia), AL-108, AL-208, nerve growth factor antagonist (pain), SLV-317, CGX-1007, INNO-105, oral teriparatide (eligen), GEM-OS1, AC-162352, PRX-302, LFn-p24 fusion vaccine (Therapore), EP-1043, Streptococcus pneumoniae (S pneumoniae) pediatric vaccine, malaria vaccine, Neisseria meningitidis group B vaccine, neonatal group B streptococcal vaccine, anthrax vaccine, HCV vaccine (gpE1+gpE2+MF-59), otitis media therapy, HCV vaccine (core antigen + ISCOMATRIX), hPTH (1-34) (transdermal, ViaDerm), 768974, SYN-101, PGN-0052, aviscumnine, BIM-23190, tuberculosis vaccine, multi-epitope tyrosinase peptides, cancer vaccines, enkastim, APC-8024, GI-5005, ACC-001, TTS-CD3, vascular-targeted TNF (solid tumors), desmopressin (oral controlled release), onercept, and TP-9201.

[0210] In some embodiments, the polypeptide is adalimumab (HUMIRA), infliximab (REMICADE TM ), rituximab (RITUXAN TM / MAB THERA TM ), etanercept (ENBREL TM ), bevacizumab (AVASTIN TM ), HERCEPTIN TM )、pegrilgrastim(NEULASTA TM ), or any other suitable polypeptide, including biosimilars and biobetters.

[0211] Other suitable polypeptides are those listed below and in Table 1 of US2016 / 0097074:

[0212] Table 1

[0213]

[0214] Table 1

[0215]

[0216] Table 1

[0217]

[0218] Table 1

[0219]

[0220] Table 1

[0221]

[0222] Table 1

[0223]

[0224] In an embodiment, the polypeptide is a hormone, a coagulation / clotting factor, a cytokine / growth factor, an antibody molecule, a fusion protein, a protein vaccine or a peptide, as shown in Table 2.

[0225] Table 2: Exemplary products

[0226]

[0227]

[0228]

[0229]

[0230] In an embodiment, the protein is a multispecific protein, such as a bispecific antibody as shown in Table 3.

[0231] Table 3: Bispecific formats

[0232]

[0233]

[0234]

[0235]

[0236]

[0237] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice and / or testing of the present disclosure, preferred materials and methods are described herein. In describing and claiming the present disclosure, the following terms are used according to how they are defined where definitions are provided.

[0238] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0239] The articles "a" and "an" are used herein to refer to one or more than one (ie, at least one) of the grammatical object of the article. For example, "module unit" can mean one module unit or more than one module unit.

[0240] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and illustrative examples, make and utilize the customizable facility of the present disclosure.

[0241] Although the present invention has been disclosed with reference to specific aspects, it is obvious that other aspects and changes of the present invention can be designed by those skilled in the art without departing from the true spirit and scope of the present invention. The appended claims are intended to be interpreted as including all such aspects and equivalent changes.

Claims

1. A method for constructing a customizable facility, the method comprising: providing a housing comprising at least one side wall and a roof, wherein the housing is supported on a footing fixed to the ground; supporting a bioreactor on a floor within the housing; installing first-stage features in the first stage on the ground, the first-stage features comprising an air-controlled entryway, a gowning area, a utility area, a first manufacturing wing, a first office space, a first set of modular units, and at least one corridor connecting at least two first-stage features to each other, the first set of modular units having a first modular unit being a fermentation unit, a second modular unit being a pre-viral unit, a third modular unit being a post-viral unit, a fourth modular unit being a fill-finished product unit, a fifth modular unit being a dosage compounding unit, and a sixth modular unit being a packaging unit; installing in a second phase second phase features, the second phase features comprising a second manufacturing wing, a second office space, and a second group of modular units, the second group of modular units having a seventh modular unit being a fermentation unit, an eighth modular unit being a pre-viral unit, a ninth modular unit being a post-viral unit, a tenth modular unit being a fill-finished product unit, an eleventh modular unit being a dosage formulation unit, and a twelfth modular unit being a packaging unit, the second group of modular units being vertically located on at least one level above the bioreactor and the first group of modular units; and installing additional features in at least one subsequent stage, the additional features comprising additional groups of module units and additional manufacturing wings, wherein the additional feature is positioned horizontally or vertically adjacent to the first manufacturing wing or the second manufacturing wing, and Wherein the customizable facility is configured to manufacture at least one pharmaceutical product.

2. The method of claim 1, wherein the infill-finished unit of the second set of modular units has a single floor with a floor area of ​​1,500 square meters.

3. The method of claim 2, wherein the fill-finished unit further comprises a mid-level for an HVAC plant room.

4. The method of claim 2, wherein the fill-finish unit further comprises a free space disposed directly adjacent to the fill-finish unit, the free space together with the fill-finish unit having a floor area of ​​3,000 square meters.

5. The method of claim 1, wherein the first group or the second group of module units comprises a 2k module having a single layer with a footprint of 1,500 square meters, the 2k module being capable of sealing a 2,000 liter container.

6. The method of claim 5, wherein the 2k module further comprises a mid-level for an HVAC plant room.

7. The method of claim 5, wherein the 2k module further comprises a free field disposed directly adjacent to the 2k module, the free field together with the 2k module having a footprint of 3,000 square meters.

8. The method of claim 1, wherein the first group or the second group of modules comprises a 5k module alone, the 5k module having a single layer with a footprint of 3,000 square meters, the 5k module being capable of sealing a 5,000 liter container.

9. The method of claim 8, wherein the 5k module further comprises a mid-level for an HVAC plant room.

10. The method of claim 1, wherein the first group or the second group of modules comprises a single 15k module, the 15k module having a first layer and a second layer.

11. The method of claim 10, wherein the 15k module has a footprint of 3,000 square meters and can seal a 15,000 liter container.

12. The method of claim 10, wherein the 15k module further comprises a local HVAC unit, a clean-in-place (CIP) unit, and a temperature control unit (TCU).

13. The method of claim 10, wherein the second layer of the 15k modules extends vertically above the first layer of the 15k modules.

14. The method of claim 10, wherein the first layer of the 15k modules and the second layer of the 15k modules together have an area of ​​6,000 square meters.

15. The method of claim 1, wherein the customizable facility comprises a 20k module having a first layer, a second layer, and a third layer.

16. The method of claim 15, wherein the 20k module has a footprint of 3,000 square meters and can seal a 20,000 liter container.

17. The method of claim 15, wherein the second layer of the 20k module extends vertically over the first layer of the 20k module, and the third layer of the 20k module extends vertically over the first layer of the 20k module and the second layer of the 20k module.

18. The method of claim 15, wherein the first layer of the 20k modules, the second layer of the 20k modules, and the third layer of the 20k modules together have an area of ​​9,000 square meters.

19. The method of claim 1, wherein the customizable facility further comprises a yard directly adjacent to the customizable facility, the yard comprising a processing area for processing equipment and materials.

20. The method of claim 1, wherein said customizable facility further comprises a warehouse area sealed within said housing.

21. A customizable facility for manufacturing at least one pharmaceutical product, comprising five rows of zones, said customizable facility comprising: a first row, which contains a plurality of purification zones; the second row, which contains multiple fermentation zones; a third row, which includes at least one central utility zone; the fourth row, which contains multiple fermentation zones; a fifth row comprising a plurality of purification zones; and An expansion that adds two additional purification zones to the first row, two additional fermentation zones to the second row, two additional fermentation zones to the fourth row, and / or two additional purification zones to the fifth row.

22. The customizable facility of claim 21, wherein the facility does not include a housing.

23. The customizable facility of claim 21 wherein said central utility zone provides utility to each of said other zones.

24. The customizable facility of claim 21, wherein the first row comprises three purification zones, the second row comprises three fermentation zones, the fourth row comprises three fermentation zones, and / or the fifth row comprises three purification zones.

25. The customizable facility of claim 21 further comprising a utility extension that adds additional utility area to said third row.

26. The customizable facility of claim 21, further comprising a housing that encloses all of said first row through said fifth row.

27. The customizable facility of claim 21, wherein the second row is adjacent to the first row, the third row is adjacent to the second row, the fourth row is adjacent to the third row, and the fifth row is adjacent to the fourth row.

28. The customizable facility of claim 25, wherein the expansion adds two additional purification zones to the first row, two additional fermentation zones to the second row, two additional fermentation zones to the fourth row, and two additional purification zones to the fifth row.

29. The customizable facility of claim 28, wherein said expansion further adds an equal number of additional purification zones to said first row and said fifth row, and an equal number of additional fermentation zones to said second row and said fourth row.

30. The customizable facility of claim 21, wherein the expansion further comprises at least one additional purification zone to the first row, at least one additional fermentation zone to the second row, at least one additional fermentation zone to the fourth row, and / or at least one additional purification zone to the fifth row.